AXGN · 10-Q · 2026Q1

Axogen, Inc.

Filed 2026-04-28 · Healthcare

Ranked Events

• Reimbursement and Payer MixImportance 85 · Surprise 92
  The company reported positive coverage decisions from two major U.S. commercial insurers, Cigna and Elevance Health, which can increase payer access and reduce reimbursement uncertainty in the U.S. market. Effective…
• Operating Expense TrendsImportance 84 · Surprise 74
  Total operating costs and expenses increased 34.0% year-over-year to $49,021 in Q1 2026, led by a 36.1% rise in sales and marketing and a 36.1% rise in general and administrative expense. The increases were primarily…
• R&D Spend and Clinical TrialsImportance 79 · Surprise 66
  R&D expense increased to $7,517 for the three months ended March 31, 2026, a 23.4% rise year-over-year, and now represents 12.2% of revenue. The composition of R&D shifted: clinical trial costs comprised approximately…
• Product Launch and TransitionImportance 71 · Surprise 60
  On December 3, 2025, the FDA approved the BLA for Avance, Axogen's acellular nerve allograft product, marking a major regulatory milestone. Continued market access depends on verification and description of clinical…
• Revenue Concentration RiskImportance 71 · Surprise 60
  While Axogen offers nerve repair products in the U.S., Canada, Germany, the United Kingdom, Spain and several other countries, the Company derives substantially all of its revenues from sales of its nerve repair products to customers in the U.S.,This geographic concentration means U.S. reimbursement changes (e.g., the new CMS Level 3 Nerve Procedure Code effective January 1, 2026) and commercial insurer coverage decisions materially affect revenue; for example, the Company reported higher Avance facility reimbursement increases year-over-year tied to the CMS code change.,The Company's strategy emphasizes deeper penetration of Level 1 trauma centers and academic-affiliated hospitals in the U.S., underscoring the revenue concentration in that geography.
• Liquidity and Cash PositionImportance 71 · Surprise 60
  As of March 31, 2026 the company reported cash, cash equivalents and investments totaling $101,601 (amounts presented in thousands in the filing). The increase in cash and investments from December 31, 2025 was…
• Outstanding IndebtednessImportance 71 · Surprise 60
  On January 23, 2026 the company completed an upsized public offering that generated net proceeds of $133,252 (amounts in thousands), from which $69,707 was used to fully repay and terminate the company’s Credit…
• Capital Raise and Use of ProceedsImportance 71 · Surprise 60
  On January 23, 2026, Axogen closed an upsized public offering with the sale of 4,600,000 shares of common stock, yielding net proceeds of $133,252.,From these net proceeds, $69,707 were used to fully repay and terminate the Company's Credit Facility on January 28, 2026.,The filing states remaining funds from the offering are available for working capital, capital expenditures and other general corporate purposes as of Q1 2026.
• Regulatory Approval MilestonesImportance 65 · Surprise 60
  On December 3, 2025 the FDA approved the BLA for Avance, representing a U.S. regulatory milestone for the company. Continued approval is conditioned on verification and description of clinical benefits in confirmatory…
• Operating Cash Flow ImprovementImportance 65 · Surprise 82
  Net cash provided by operating activities was $1,565 during the three months ended March 31, 2026 as compared to net cash used in operating activities of $13,179 during the three months ended March 31, 2025.,The increase in net cash provided by operating activities of $14,744, or 111.9%, was primarily due to a net favorable change in non-cash charges and working capital accounts of $20,487 and $10,179, respectively, partially offset by an increase in net loss of $15,750.,Improved working capital and non-cash adjustments were the main drivers converting prior year operating cash use into positive operating cash flow in Q1 2026.
• Gross Margin DriversImportance 64 · Surprise 56
  Gross profit increased 32.2% year-over-year and gross margin expanded to 75.2% for Q1 2026, reflecting improvements in product-level economics. Management attributes higher margins to lower inventory write-offs and…
• Revenue Performance and MixImportance 59 · Surprise 48
  Total revenues increased 26.6% year-over-year to $61,457 for Q1 2026, driven primarily by higher unit volume and the impact of price changes. Growth was broad-based enough to lift gross profit by 32.2% to $46,189 and…
• Occupancy and Leasing ActivityImportance 56 · Surprise 24
  Contractual operating and finance lease obligations aggregate $30,410 as presented in the Contractual Obligations and Commitments table included in the Q1 2026 MD&A.,The table discloses multi‑year lease commitments (reported across near term and later periods) that total $30,410 and the Company refers readers to Note 7 for additional lease details.,These lease obligations represent a material contract commitment on the balance sheet and are recorded as operating and finance lease liabilities under ASC 842 (detailed in the Notes).
• Investing Activities - PurchasesImportance 52 · Surprise 42
  Net cash used in investing activities for the three months ended March 31, 2026 was $15,964 compared to net cash provided by investing activities of $1,339 for the three months ended March 31, 2025.,The unfavorable change of $17,303 was primarily due to the purchase of $19,000 of investments and an increase in purchases of property and equipment of $2,533 during Q1 2026, partially offset by sales of $4,000 of investments.,The Company’s investing activities in Q1 2026 shifted from net inflows to net outflows driven largely by short-term investment purchases (U.S. Treasuries and corporate bonds) as it managed the proceeds from the January offering.
• Geographic Revenue ShiftImportance 37 · Surprise 6
  Although Axogen markets products in the U.S., Canada, Germany, the U.K., Spain and other countries, the company states that it derives substantially all of its revenues from the U.S. Axogen’s commercial efforts,…
• Customer DynamicsImportance 35 · Surprise 30
  Axogen’s commercial strategy targets deepening presence in high-potential accounts, specifically Level 1 trauma centers and academic-affiliated hospitals with many trained microsurgeons. The company plans to drive…
• Strategic Initiatives and TargetingImportance 34 · Surprise 42
  The company’s stated strategy is to deepen presence in high‑potential accounts, specifically Level 1 trauma centers and academic‑affiliated hospitals with many trained microsurgeons, to drive adoption of its nerve…
• Macroeconomic Factors ImpactImportance 10 · Surprise 6
  The company identifies exposure to the evolving macroeconomic environment, including financial market volatility, geopolitical tensions and escalating trade disputes with U.S. trading partners, that could affect demand…
• Income Tax PositionImportance 6 · Surprise 6
  The Company had no material income tax expense or benefit during the three months ended March 31, 2026 and 2025 due to the incurrence of net operating losses in both periods, and related tax benefits remain fully reserved by a valuation allowance.,During Q1 2026 the IRS completed its examination of the Company's 2021 federal income tax return with no material findings.,Management does not believe there are any material additional tax expenses or benefits pending from current examinations as of March 31, 2026.

Revenue by Geography (in thousands)